IMMUNEX WILL PUT MDR REVERSAL AGENT INTO CLINIC THIS YEAR
Executive Summary
IMMUNEX WILL PUT MDR REVERSAL AGENT INTO CLINIC THIS YEAR, acting Chairman and CEO Steven Gillis predicted at the Hambrecht & Quist 12th Annual Life Sciences Conferences in San Francisco Jan. 11. The multiple drug resistance gene inhibitor agent is one of three drugs from the Lederle Oncology portfolio that will begin clinicals in 1994.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: